Hepatitis C : Bulletin #3
This edition presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) infection market. Topics covered include: Medivir AB communicating an update on the results of its triple combination JNJ-4178 (simeprevir/odalasvir/AL-335) in an ongoing Phase II study; AbbVie announcing positive data from two Phase III studies, ENDURANCE-3 and EXPEDITION-1, with its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Merck & Co. announcing positive results from the Phase II C-SURGE study in which MK-3682B, its triple-combination of uprifosbuvir, grazoprevir and rusazvir, which is being investigated in treatment-experienced GT1 patients for whom treatment with approved direct-acting antiviral (DAA) regimens has previously failed.
Reasons to Purchase
Are KOLs impressed by JNJ-4178’s efficacy in treatment-naïve, GT1, non-cirrhotic HCV patients?
Will JNJ-4178’s 6-week treatment duration provide it with a competitive edge over competing 8-week HCV regimens?
Do KOLs think that JNJ-4178 will prove to be effective in other HCV genotypes?
Could the increasing availability of pan-genotypic HCV therapies limit JNJ-4178’s success?
How do KOLs view G/P’s pan-genotypic performance in the EXPEDITION-1 and ENDURANCE-3 studies?
Do KOLs expect G/P to satisfy any unmet therapeutic needs within the HCV market, such as for GT3 infected or renally-insufficient patients?
What role will pricing and marketing play in terms of helping G/P to establish a position within the HCV treatment paradigm?
How do KOLs rate MK-3682B’s response rates for treatment-experienced GT1 patients in the Phase II C-SURGE study?
Is MK-3682B destined to become a salvage therapy for DAA-experienced HCV patients?
How large is the patient pool for MK-3682B likely to be given the high success rates achieved by DAA regimens for treating HCV?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook